ROCHESTER, MI -- (Marketwire) -- 01/03/13 -- OPTIMIZERx Corp. (OTCQB: OPRX) is pleased to announce that the United States Patent and Trademark Office issued on December 25th, 2012 U.S. Patent No. 8,341,015, which provides the Company patent protection for SampleMD's eCoupon technology.
"This is exciting news for everyone one who has worked so hard to develop and integrate SampleMD's savings and support technology. Our mission is to share our patented technology with all ePrescribing and EHR platforms to allow more doctors to help more patients start and stay on their medications," said David Harrell, Founder of OPTIMIZERx.
SampleMD has been the innovator in delivering savings and support within physicians' electronic workflow since its launch in 2010. SampleMD is currently distributing hundreds of thousands of trial vouchers, co-pay savings and other educational support each quarter -- right at point of prescription -- to help patients better afford and take their prescribed medicines.
The awarded claims cover SampleMD's ability to electronically process, display and distribute eligible prescription savings on the medications and therapies healthcare providers wish to prescribe for their patients. The company has also recently submitted and will be preparing additional filings to protect its intellectual property on forthcoming solutions that will further assist and support physicians, pharmacists and patients.
Harrell further explained, "OPTIMIZERx, with the help and insights of our healthcare partners, will continue to develop technology to meet the needs of the evolving healthcare industry. We will continue to develop our suite of technology solutions to seamlessly integrate within the EHR environment to capitalize on its growth and adoption and e-prescribing -- while minimizing workflow interruptions for physicians. Our solutions are built around establishing both process and technology standards for compliance and interoperability to reach enormous scale, along with reporting that meets industry data requirements while offering new insights."
About SampleMD|OPTIMIZERx Corp
OPTIMIZERx Corp. (OTCQB: OPRX) provides unique consumer and physician platforms to help patients better afford and comply with their medicines and healthcare products, while offering pharmaceutical and healthcare companies effective ways to expand patient awareness, access and adherence to their medications. For more information, please go to www.optimizerxcorp.com or www.samplemd.com.
This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended and such section 21E of the Securities Act of 1934, amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Most Popular Stories
- Fed Committee Optimistic About Growth Prospects
- Pot's Legal in WA -- But You Should Probably Ask Your Boss
- How ESPN Became a $50B Sports Empire
- Drive-In Movie Theaters Use Creativity to Afford Digital Switch
- Obama Cites Letter Writers in Pitching Economy
- Pau Gasol Turns Down Lakers' Offer
- U.S. Immigration Courts Facing Record Backlog
- President Obama Relishes Roadshow, but Agenda Still Stuck
- Stevie Fielder Changes Tune on Thad Cochran Vote-buying Story
- Farrell, Kitsch Rumored for Season 2 of 'True Detective'